Table 3.

Correlation between integrity of cfDNA and clinical characteristics.

Variables	Before chemotherapy	After chemotherapy
Gender
Male	6.96 ± 1.14	3.78 ± 0.40
Female	6.95 ± 1.24	3.81 ± 0.42
P	0.9635	0.6911
Age
>65	7.09 ± 1.20	3.86 ± 0.40
≤65	7.27 ± 1.37	3.83 ± 0.41
P	0.5037	0.7168
Tumor site
Colon	6.94 ± 1.34	3.83 ± 0.40
Rectum	7.13 ± 1.25	3.86 ± 0.45
P	0.4430	0.6997
TNM stage
II/III	7.15 ± 1.33	3.83 ± 0.47
IV	6.92 ± 1.14	3.85 ± 0.43
P	0.1105	0.8130
Tumor differentiation
Low-medium	7.38 ± 0.99	3.88 ± 0.40
High	6.31 ± 1.30	3.56 ± 0.47
P	<0.0001	0.0003
CA125
≥35 U/ml	7.26 ± 1.97	4.12 ± 0.39
<35 U/ml	6.85 ± 1.21	3.98 ± 0.37
P	0.2178	0.0573
CEA
≥3.5 ng/mL	7.80 ± 1.17	3.85 ± 0.45
<3.5 ng/mL	7.74 ± 1.09	3.76 ± 0.43
P	0.7831	0.2881
NSE
≥16.3 ng/mL	7.41 ± 1.27	3.74 ± 0.35
<16.3 ng/mL	7.65 ± 1.01	3.84 ± 0.41
P	0.3333	0.1857
AFP
≥7 ng/mL	7.56 ± 1.08	3.83 ± 0.44
<7 ng/mL	7.34 ± 1.21	3.94 ± 0.52
P	0.3363	0.2481
E-cadherin
High expression	7.07 ± 1.27	3.81 ± 0.50
Low expression	7.05 ± 1.26	3.91 ± 0.48
P	0.9381	0.3267
VEGF
High expression	7.18 ± 1.32	3.84 ± 0.41
Low expression	6.96 ± .1.14	3.90 ± 0.36
P	0.2948	0.4550
mTor
High expression	7.05 ± 1.22	3.84 ± 0.48
Low expression	7.08 ± 1.38	3.91 ± 0.35
P	0.9058	0.4317
MMP-9
High expression	7.05 ± 1.31	3.86 ± 0.44
Low expression	7.07 ± 1.17	3.81 ± 0.43
P	0.9324	0.5410

Bold values mean P < 0.01.